中度剂量递增在复发或第二原发头颈癌再程放疗中的价值
本研究回顾性分析了2010至2019年间48例复发或第二原发头颈癌患者的再程放疗管理及结局,中位再程放疗剂量58.4 Gy,中位OS为25个月,1年OS为62.4%,中位PFS为9个月,1年PFS为37.6%。单因素分析显示较低的rT分期和放疗推量(boost)与OS改善相关,>50 Gy及完成放疗有OS获益趋势。现代放疗技术再程放疗的生存率令人鼓舞,毒性可接受。
要点
- 中位再程放疗剂量58.4 Gy,治疗完成率87.5%,中位OS为25个月。
- 较低的rT分期和放疗推量与OS改善显著相关(p<0.05)。
- 10.4%患者出现至少1项3级急性毒性,27.3%出现慢性≥3级毒性。
核心结论
- 采用现代放疗技术(如调强放疗)再程放疗复发或第二原发头颈癌可获得令人鼓舞的生存率,毒性可接受。
- 增加再程放疗剂量、使用放疗推量以及完成再程放疗可改善生存。
研究设计与样本
- 回顾性研究,纳入2010至2019年间在弗莱堡大学医学中心接受再程放疗的48例复发或第二原发头颈癌患者。
- 采用Kaplan-Meier法计算OS和PFS,单因素Cox回归分析评估临床病理因素对治疗结局的影响。
- 急性和慢性治疗相关毒性采用CTCAE v4.03量化。
主要发现
- 28例(58.3%)接受同步化疗,其中西妥昔单抗是最常用的系统性药物(n=17,60.7%)。
- 首次与第二次放疗的中位间隔时间为17个月(范围4个月至176个月)。
- 中位OS为25个月,1年OS为62.4%;中位PFS为9个月,1年PFS为37.6%。
- 5例(10.4%)出现至少1项3级毒性,9例(27.3%)出现慢性≥3级毒性,包括1例(3.0%)4级颈动脉破裂和1例(3.0%)4级放射性骨坏死。
关键数值与推荐
- 较低的rT分期和放疗推量与OS改善相关(p<0.05)。
- 接受>50 Gy的患者OS有优于趋势(p=0.091)。
- 完成 prescribed 放疗的患者OS有优于趋势(p=0.055)。
临床怎么用
- 对于复发或第二原发头颈癌,可考虑采用现代放疗技术进行再程放疗,并争取完成治疗。
- 在安全前提下,可考虑增加再程放疗剂量或使用放疗推量以改善生存。
- 需密切监测并管理再程放疗相关毒性,尤其是慢性高级别毒性。
局限性
- 回顾性研究,样本量较小(48例)。
- 单因素分析,未进行多因素校正。
- 来自单中心经验,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for local and locoregional recurrence or second head-and-neck (H&N) cancers after previous radiotherapy is challenging, and re-irradiation carries a significantly increased risk for radiotherapy-related normal tissue toxicities and treatment failure due to a radioresistant tumor phenotype. Here, we analyzed re-irradiation management and outcomes in patients with recurrent or second primary H&N carcinoma using state-of-the-art diagnostic procedures and radiotherapy techniques. METHODS: Between 2010 and 2019, 48 patients with recurrent or second primary H&N carcinoma received re-radiotherapy at the University of Freiburg Medical Center and were included in this study. Overall survival (OS) and progression-free survival (PFS) were calculated with the Kaplan-Meier method, and univariate Cox-regression analyses were performed to assess the effects of clinico-pathological factors on treatment outcomes. Acute and chronic treatment-related toxicities were quantified using the Common Terminology Criteria for Adverse Events (CTCAE v4.03). RESULTS: Thirty-one patients (64.6%) received definitive and 17 (35.4%) adjuvant radiotherapy. Simultaneous chemotherapy was administered in 28 patients (58.3%) with cetuximab as the most commonly used systemic agent (n = 17, 60.7%). After a median time of 17 months (range 4 months to 176 months) between first and second radiotherapy, patients were re-irradiated with a median of 58.4 Gy and a treatment completion rate of 87.5% (n = 42). Median OS was 25 months with a 1-year OS amounting to 62.4%, and median PFS was 9 months with a 1-year PFS of 37.6%. Univariate analyses demonstrated that both a lower rT-status and a radiotherapy boost were associated with improved OS (p < 0.05). There was a trend towards superior OS for patients who received > 50 Gy (p = 0.091) and who completed the prescribed radiotherapy (p = 0.055). Five patients (10.4%) suffered from at least one grade 3 toxicities, while 9 patients (27.3%) experienced chronic higher-grade toxicities (≥ grade 3) with one (3.0%) grade 4 carotid blowout and one (3.0%) grade 4 osteoradionecrosis. CONCLUSION: Re-irradiation of recurrent or second primary H&N cancer with modern radiation techniques such as intensity-modulated radiotherapy resulted in promising survival rates with acceptable toxicities compared to historical cohorts. Increased re-irradiation doses, utilization of a radiotherapy boost and completion of the re-irradiation treatment were found to result in improved survival.
引用
- Rühle A, Sprave T, Kalckreuth T, et al. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiat Oncol. 2020. PMID: 32299456. doi:10.1186/s13014-020-01531-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。